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Point mutations of the human parathyroid calcium receptor gene are
not responsible for non-suppressible renal hyperparathyroidism. The
calcium-dependent secretion of parathyroid hormone (PTH) is mediated
through an extracellular G protein-coupled calcium receptor (CaR).
Inactivating point mutations of this receptor have been found in familial
hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.
These diseases feature a decreased calcium sensitivity of the parathyroid
glands, resulting in a rightward shift of the Ca21-PTH relationship. Severe,
non-suppressible renal hyperparathyroidism (rHPT) is often characterized
by similar setpoint shifts to the right. Thus, point mutations of the CaR
gene could contribute to non-suppressible rHPT. We examined genomic
DNA of hyperplastic or mainly nodular tissues of 39 parathyroids from 25
rHPT-patients with resistance to calcitriol therapy. Amplification of the six
exons of the CaR gene was followed by single-strand conformation
polymorphism (SSCP) analysis. DNA sequencing was performed where
band shifts were observed. No point mutations in the coding sequence of
the CaR gene were detected using the PCR-SSCP strategy. Point muta-
tions in the coding regions of the CaR gene probably play no role in the
evolution of renal HPT and are not responsible for the calcitriol resistance
of PTH secretion.
The blood level of parathyroid hormone (PTH) is tightly
regulated by 1,25(OH)2D3 (calcitriol) and extracellular calcium.
Calcitriol acts directly on the parathyroids by suppression of PTH
gene transcription [1–5] and indirectly by increasing the plasma
Ca21 concentration, while the plasma calcium determines the
minute-to-minute secretion of PTH by the parathyroid glands.
The relationship between Ca21 and PTH can be expressed by an
inverse sigmoidal curve [6–8], wherein the setpoint of PTH
secretion is defined as the calcium concentration at which PTH
secretion is suppressed to the midpoint of the curve (that is, Ca21
at (PTHmax 1 PTHmin)/2).
In early renal failure secondary (renal) hyperparathyroidism
(rHPT) evolves as a compensation for the decreased capacity of
the kidneys to synthesize 1,25(OH)2D3. Without effective sup-
pression through calcitriol upon PTH expression and cellular
proliferation [9], and under the driving force of hypocalcemia,
large amounts of PTH are secreted by the hyperplastic parathy-
roids.
In advanced hyperparathyroidism, active vitamin D metabolites
are applied in high doses to suppress parathyroid growth and PTH
secretion. However, in the course of rHPT the parathyroids
frequently escape suppression by calcitriol (“calcitriol resis-
tance”), since hypercalcemia and hyperphosphatemia limit the use
of vitamin D. These patients have to undergo surgery. The basis of
calcitriol resistance is not yet clear: it could be due to increased
parathyroid mass, reduced focal vitamin D receptor (VDR)
concentration [10, 11], altered calcium sensitivity, altered down-
stream transmission of the calcium signal, occurrence of mono-
clonal growth [12, 13], or a combination of these factors.
Non-suppressible rHPT patients often show a rightward shift of
the calcium setpoint and a slighter slope [6–8], indicating abnor-
mal calcium-sensing. Calcium-sensing of the parathyroids is me-
diated by the G protein-coupled calcium receptor (CaR) [14, 15].
The predicted 120 kDa protein consists of a large extracellular
N-terminal domain, seven transmembrane helices and an intra-
cellular C-terminal domain with several phosphorylation sites.
After ligand binding via G-protein modulation the CaR activates
two major second messenger systems (cAMP and IP3) [reviewed
in 16–18]. The signal pathway involving IP3 leads to the release of
Ca21 from intracellular stores. A short-term effect of increasing
extracellular Ca21 concentration is the suppression of exocytosis
of stored PTH from secretory granules [8]. A long-term effect is
the repression of PTH gene transcription [reviewed in [19]].
Mutations of the human parathyroid CaR gene have been found
in diseases showing an altered calcium setpoint of PTH secretion.
In familial hypocalciuric hypercalcemia (FHH) and neonatal
severe hyperparathyroidism (NSHPT), inactivating point muta-
tions of the CaR gene cause a decreased calcium sensitivity
[20–22]. In autosomal dominant hypocalcemia, a gain of function
mutation of the CaR gene decreases the calcium setpoint of PTH
secretion [23].
The physiological similarities between FHH and rHPT
prompted us to examine whether point mutations of the human
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parathyroid CaR gene give rise to non-suppressible rHPT in at
least some patients. Thus, we screened the coding regions of the
CaR gene for mutations using single-strand conformation poly-
morphism (SSCP) analysis [24, 25].
METHODS
Patients and tissues
We obtained 39 single parathyroids from 25 patients (16
females, 9 males) with rHPT and the corresponding blood. All
rHPT patients had been clinically characterized as non-suppress-
ible with standard therapy (Fig. 1) and underwent surgical treat-
ment (Table 1). Some patients (numbers 9, 12, 13, 15, 17, 20, 25)
merely had secondary hyerparathyroidism. They were not hyper-
calcemic, however, a parathyroidectomy (PTX) was scheduled by
the treating nephrologists because of uncontrolled hyperphos-
phatemia. The tissues were histologically defined as mainly hyper-
plastic, micronodular or nodular. For comparison we analyzed
one autotransplant with recurrent hyperparathyroidism from a
female with juvenile primary hyperparathyroidism (pHPT) and
one gland from a male with parathyroid carcinoma. Positive
controls with known point mutations of the CaR were unavailable.
Isolation of DNA
Genomic DNA was isolated from single parathyroid glands
using TRIzol reagent (Gibco BRL, Eggenstein, Germany) [26] or
proteinase K treatment. Total DNA from whole blood was
purified with the QIAamp Blood Kit (Qiagen, Hilden, Germany).
Polymerase chain reaction
The six exons of the human CaR gene were amplified from
genomic DNA using 10 previously described primer pairs [20].
For the amplification of exon 6 area D two new primers, 6DR2
(59-TCTGGCCGCTGGTCTCCACC-39) and 6DF2 (59-AAACG-
GACTTAGATCTG-ACC-39), were used in combination with the
sense-primer 6DF (product 6D1) and the antisense-primer 6DR
(product 6D2), respectively [20]. The polymerase chain reaction
(PCR) was performed in a 50 ml reaction under standard condi-
tions [5 minutes pre-denaturation at 95°C; 35 cycles of 40 seconds
denaturation at 95°C, 90 seconds of annealing at 50°C (exon 6D2),
60°C (exons 2, 3B, 6A and 6D1), 64°C (exons 1 and 4), 65°C
(exons 3A and 6B), 68°C (exon 6C) and 69°C (exons 5 and 6D),
respectively, two minutes elongation at 72°C; finally seven minutes
at 72°C] using SuperTaq DNA polymerase (MoBiTec, Go¨ttingen,
Germany). Since SSCP is more sensitive with smaller fragments,
four amplification products were digested with restriction en-
zymes (exon 3 part A and B with EcoRV, exon 6 part B with BglI,
exon 6 part D with PstI) before SSCP analysis. Restriction was
carried out with 7 ml PCR product in a total volume of 10 ml under
the conditions recommended by the suppliers.
Single-strand conformation polymorphism analysis
Volumes of 2.5 to 3.5 ml PCR product and 5 ml of the digested
PCR product were analyzed on a vertical native gel using 0.53
concentrated mutation detection enhancement (MDE) gel matrix
(Biozym, Hess. Oldendorf, Germany) containing 5% glycerol.
Prior to loading, the samples were denatured for 10 minutes at
95°C in a formamide loading buffer (95% formamide, 5% glyc-
erol, 10 mM EDTA, 0.25% bromophenol blue, 0.25% xylencyanol
FF) and cooled to 4°C. Single-strand conformation polymorphism
(SSCP) was carried out for 16 hours at 2 Watts and 10°C. For the
PCR product of exon 6D1 we used electrophoresis temperatures
of 10°C and 17°C. The bands were detected by silver staining [27].
Sequencing
Radioactive (35S-dATP) sequencing of the PCR products was
performed using PCR primer and the “Sequenase PCR product
sequencing kit” (Amersham USB, Braunschweig, Germany). Five
microliters of PCR product were directly applied to the sequenc-
ing reaction. The sequencing of the PCR product of exon 6D1 was
performed with an automatic sequencer (ABI Prism 310 Genetic
Analyzer; Perkin Elmer, Weiterstadt, Germany) using the “Dye
Terminator Cycle Sequencing Kit” (Perkin Elmer).
RESULTS
We screened 39 parathyroid glands and corresponding blood
from 25 patients with non-suppressible rHPT, one recurrent
hyperparathyroidism in an autograft from a female, and one
parathyroid carcinoma for point mutations in the coding region of
their parathyroid calcium-sensing receptor gene. The 10 amplifi-
cation products enclosing the coding region of the CaR gene
(exons 1, 2, 3A, 3B, 4, 5, 6A-D) were analyzed by SSCP. After
denaturation of the PCR products, the single strands were
separated on a native gel. With this method point mutations
should be visible as band shifts of the single strands.
The amplification product of exon 5, containing flanking intron
sequences on both sides of the coding region, exhibited three
different band patterns in the SSCP analysis (Fig. 2). Pattern I
occurred in 56% (14 of 25) of the rHPT-patients, pattern II in 8%
(2 of 25) and pattern III in 36% (9 of 25). The recurrent pHPT
autograft exhibited pattern III and the parathyroid carcinoma
pattern I. The sequence analysis of two probes of each pattern
showed no alterations in the coding region of the probes, except
in the 59 flanking intron (intron 4). At position 288 (in relation to
Fig. 1. Ionized calcium-parathyroid hormone (PTH) relationships before
parathyroidectomy in 27 patients. PTH values are depicted logarithmi-
cally (normal range for PTH is 1.1 to 5.8 pmol/liter and for ionized calcium
1.11 to 1.33 mmol/liter).
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the intron 4/exon 5 splice site) we observed a pattern-dependent
polymorphism: pattern I probes were homozygous for “T”, pat-
tern II probes were homozygous for “C” and pattern III probes
were heterozygous (Fig. 3).
The amplification products containing exons 1, 2, 3 (3A, 3B), 4
and 6 (6A-D) showed no differences in their band patterns. Figure
4 represents a typical SSCP result without band shifts. Although
the occurrence of three polymorphisms in exon 6 part D has been
previously reported [22], we were not able to detect them in the
PstI-digested amplification products of exon 6D in the SSCP. By
using two new primer combinations (6DF/6DR2 and 6DF2/6DR)
two overlapping subfragments of exon 6 part D were amplified
(6D1 including the 3 polymorphisms and 6D2) and analyzed by
SSCP at two different electrophoresis temperatures (10°C and
17°C). Since we did not find conclusive evidence for the occur-
rence of the polymorphisms in 6D1 (only 2 or 3 slightly differing
band patterns), we directly sequenced the 6D1-PCR products of
all patients. We found the polymorphisms in the following allelic
frequencies: at nucleotide position 3330 GCC3TCC (A986S) in
70%, at position 3342 GGG3AGG (G990R) in 93% and at
position 3403 CAG3GAG (Q1100E) in 8%.
DISCUSSION
Advanced severe renal hyperparathyroidism (rHPT) is charac-
terized by an excessive increase of parathyroid mass [28] and
sometimes abnormal calcium sensing [4, 8, 29]. In congenital
diseases with abnormal calcium sensing, nearly 30 different point
mutations of the CaR gene have been detected so far [20–22, 30;
reviewed in 31]. In familial hypocalciuric hypercalcemia (FHH)
and neonatal severe hyperparathyroidism (NSHPT), inactivating
Fig. 2. Single-strand conformation polymorphism (SSCP) analysis of the
amplification products of exon 5 of the parathyroid calcium receptor
(CaR) gene of renal hyperparathyroid (rHPT) patients. This section
shows the three band patterns (I-III) of the PCR product containing exon
5 with its flanking intron sequences. Lanes 1 and 2, patient 8; lanes 3 and
4, patient 7; lanes 5 and 6, patient 1.


































Gland 1 Gland 2
1 RK ADPKD 45 54 110 RTX 5.8 — 1.46 78.0 diffuse nodular
2 JT Unknown 36 38 26 HD — — 1.37 69.0 nodular —
3 HB GN 52 52 — uremia — — 1.42 45.3 nodular —
4 AT IN 31 38 80 HD — — 1.22 215.0 micronodular nodular
5 AS Unknown 49 63 172 RTX 10.8 — 1.55 20.9 diffuse nodular
6 UM Unknown 57 62 58 HD — — 1.34 159.5 diffuse nodular
7 KS Renal cancer 50 61 128 HD — 1 1.24 71.0 micronodular —
8 HV GN 47 54 80 HD, PD — — 1.21 37.0 nodular nodular
9 AL SLE 25 39 172 HD — 1 1.17 319.0 diffuse micronodular
10 FM IN 46 47 8 HD — — 1.28 83.2 nodular nodular
11 DG GN 30 37 80 RTX, PD 3.6 — 1.57 15.8 diffuse diffuse
12 EA GN 31 34 39 PD — — 1.17 140.0 diffuse —
13 UH SLE 24 31 89 HD — — 1.17 45.0 diffuse —
14 GK E605 intox. 46 54 98 HD — 2 1.39 176.0 micronodular —
15 MF DM 70 75 54 HD — — 1.08 111.1 nodular nodular
16 JB ADPKD 37 47 116 RTX 5.7 — 1.50 33.5 nodular nodular
17 EW IN 53 60 87 HD — 1 1.04 48.0 diffuse nodular
18 MF Unknown 43 51 89 RTX 6.4 — 1.50 31.6 nodular nodular
19 ES ADPKD 43 49 73 RTX 37.5 — 1.43 22.0 nodular —
20 HW ADPKD 61 69 98 HD — — 1.04 154.0 nodular nodular
21 IK ADPKD 55 58 35 HD — — 1.48 78.0 diffuse —
22 WN GN 49 56 87 HD — — 1.18 61.0 diffuse —
23 MD GN 48 53 64 HD — — 1.39 69.0 nodular nodular
24 AK GN 48 58 116 RTX 27.4 — 1.60 41.0 diffuse —
25 MV GN 17 32 179 HD — — 1.08 70.0 nodular —
26 L Parathyroid
cancer
— 46 — none — 1 1.71 41.0 micronodular —
27 SB Recurrent
juvenile HPT
— 19 — none — 1 1.26 11.0 diffuse —
Abbreviations are: ADPKD, autosomal dominant polycystic kidney disease; GN, glomerulonephritis; IN, interstitial nephritis; SLE, systemic lupus
erythematosus; HPT, hyperparathyroidism; HD, hemodialysis; PD, peritoneal dialysis; RTX, renal transplantation. Normal ranges for ionized calcium
and PTH are given in parentheses.
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mutations have been shown to cause a loss of calcium responsive-
ness. Mutations increasing the calcium sensitivity have been
demonstrated in autosomal dominant hypocalcemia [23] and
isolated autosomal dominant hypoparathyroidism [32]. Although
these traits are heritable in contrast to rHPT, we felt that
mutations in the CaR could be one important event rendering
rHPT non-suppressible.
A monoclonal cell population can arise as a consequence of a
somatic mutation such as point mutation, deletion, insertion, or
allelic loss of genes involved in cell cycle control or cell function.
The parathyroids of non-suppressible patients requiring para-
thyroidectomy have recently been shown to be monoclonal by
molecular genetic analysis [12, 13]. This raised the suspicion that,
at least in some patients with non-suppressible rHPT, mutations
of the CaR gene could be responsible for abnormalities in
Ca21-dependent PTH secretion.
Single-strand conformational polymorphism (SSCP) analysis is
a simple, rapid, and sensitive method to detect mutations in a
gene fragment [24, 25, 33]. Pearce et al were able to detect more
than 85% of CaR point mutations in their FHH and NSHPT
families using the SSCP method [21]. The sensitivity of the SSCP
in our study is confirmed by the finding of the “C/T” polymor-
phism at position 288 in intron 4. In case of “C” at this position
a Bse RI restriction site is created. The same polymorphism has
very recently and independently been described by Lovlie et al
using SSCP analysis in isolated autosomal dominant hypoparathy-
roidism [32].
Our SSCP analysis failed in detecting the three known poly-
morphisms in exon 6D, even when using a subfragment with
optimal size for SSCP (fragment 6D1 5 250 bp) and different
conditions for the electrophoresis. The polymorphisms could only
be detected by direct sequencing and occurred with the following
allelic frequencies: the A986S polymorphism in 70%, the G990R
in 93% and the Q1011E in 8%. This raised a question about the
sensitivity of our SSCP analysis, but in consideration of the
multitude of different possible combinations of these nucleotide
changes for homozygous and heterozygous alleles occurring close
to one another, the SSCP method might be unsuitable. Further-
more, Chou et al also did not find these polymorphisms using
RNAse A protection assay of the whole CaR gene from members
of 20 FHH kindreds [30]. Indeed, Hosokawa et al failed to do so
in analyzing exon 6D [34]. Therefore, the lack of detection seems
likely to be a problem restricted to exon 6D of the CaR gene.
Thus, we recommend that this fragment be sequenced directly for
mutational analysis.
Considering this, we cannot exclude that other possible muta-
tions might be covered in exon 6D. Furthermore, in the other
regions of the CaR gene some mutations might have gone
undetected by SSCP analysis, because of minor structural changes
or presence in very few cells of the total cell population investi-
gated. Despite these limitations of the SSCP analysis, our results
nevertheless indicate that point mutations of the coding regions of
the CaR gene generally do not occur in the parathyroids in rHPT.
Thus, we confirm earlier findings by Hosokawa et al, who ob-
served no mutations in the CaR gene in several parathyroid
tumors, including 12 patients with secondary HPT, using the
RNAse A-protection assay [34].
However, whether somatic mutations affecting the cascade of
post-transcriptional events or the signalling chain of the CaR or
whether specific suppressor or enhancer genes involved in the
regulation of cellular growth are involved in clonal parathyroid
proliferation remains to be elucidated. Recent work indicates that
the reduction in calcium sensitivity could be attributable to a
reduced expression of CaR mRNA or protein [35, 36].
It is well known that the expression [10, 11], the metabolism,
and the action [37] of VDR is altered in uremia. The influence of
calcitriol upon CaR expression is still controversial. Preliminary
analyses of the upstream region of the human CaR gene detected
no known motifs of vitamin D response elements [38]. However,
Brown et al described an up-regulation of CaR mRNA by
calcitriol in uremic rats [39] while Rogers et al [38] were unable to
detect any influence of altered Ca21 or calcitriol concentrations
upon CaR mRNA in chronic renal failure rats.
The links between the diminished expression and action of the
CaR and of the VDR in uremia are still far from being fully
understood. Mutations of the CaR itself are probably not respon-
sible for the clonal proliferation of the parathyroid cells in rHPT.
Thus, further research will have to focus upon the regulation of
CaR gene transcription and processing of the gene products.
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Fig. 3. Sequence comparison of the 5*-flanking intron region (intron 4)
in the amplification product of exon 5. One probe of each of the three
SSCP band patterns is represented. The nucleotides from 281 to 297 of
intron 4 are represented. At position 288 a pattern-dependent difference
in the sequence occurs. Samples showing pattern I are homozygous for
“T,” those showing pattern II are homozygous for “C” and those showing
pattern III are heterozygous.
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chain reaction; pHPT, primary hyperparathyroidism; PTH, parathyroid
homone; PTX, parathyroidectomy; rHPT, renal hyperparathyroidism;
SSCP, single-strand conformation polymorphism; VDR, vitamin D recep-
tor.
REFERENCES
1. SILVER J, RUSSELL J, SHERWOOD LM: Regulation by vitamin D
metabolites of messenger ribonucleic acid for preproparathyroid
hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA
82:4270–4273, 1985
2. SILVER J, NAVEH-MANY T, MAYER H, SCHMELZER HJ, POPOVTZER
MM: Regulation by vitamin D metabolites of parathyroid hormone
gene transcription in vivo in the rat. J Clin Invest 78:1296–1301, 1986
3. RUSSELL J, LETTIERI D, SHERWOOD LM: Suppression by 1.25(OH)2D3
of transcription of the pre-proparathyroid gene. Endocrinology 119:
2864–2866, 1986
4. DELMEZ JA, TINDIRA C, GROOMS P, DUSSO A, WINDUS DW, SLA-
TOPOLSKY E: Parathyroid hormone suppression by intravenous 1,25-
dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin
Invest 83:1349–1355, 1989
5. DEMAY MB, KIERNAN MS, DELUCA HF, KRONENBERG HM: Se-
quences in the human parathyroid hormone gene that bind the
1,25-dihydroxyvitamin D3 receptor and mediate transcriptional re-
pression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci
USA 89:8097–8101, 1992
6. BROWN EM: Four-parameter model of the sigmoidal relationship
between parathyroid hormone release and extracellular calcium con-
centration in normal and abnormal parathyroid tissue. J Clin Endo-
crinol Metab 56:572–581, 1983
7. BROWN EM: Mechanism underlying the regulation of parathyroid
hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens
2:541–551, 1993
8. FELSENFELD AJ, LLACH F: Parathyroid gland function in chronic renal
failure. (Editorial Review) Kidney Int 43:771–789, 1993
9. SZABO A, MERKE J, BEIER E, MALL G, RITZ E: 1,25(OH)2 vitamin D3
inhibits parathyroid cell proliferation in experimental uremia. Kidney
Int 35:1049–1056, 1989
10. FUKUDA N, TANAKA H, TOMINAGA Y, FUKAGAWA M, KUROKAWA K,
SEINO Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is
associated with a more severe form of parathyroid hyperplasia in
chronic uremic patients. J Clin Invest 92:1436–1443, 1993
11. GOGUSEV J, DUCHAMBON P, GIOVANNINI M, CORREZE MC, ZHANG P,
INAGAKI C, SARFATI E, DRU¨EKE T: Expression of vitamin D (vdr) and
calcium sensing receptor in normal and pathologic human parathyroid
tissue. (abstract) Nephrol Dial Transplant 10:931, 1995
12. ARNOLD A, BROWN MF, URENA P, GAZ RD, SARFATI E, DRU¨EKE TB:
Monoclonality of parathyroid tumors in chronic renal failure and in
primary parathyroid hyperplasia. J Clin Invest 95:2047–2053, 1995
13. TOMINAGA Y, KOHARA S, NAMII Y, NAGASAKA T, HABA T, UCHIDA K,
NUMANO M, TANAKA Y, TAGAKI H: Clonal analysis of nodular
parathyroid hyperplasia in renal hyperparathyroidism. World J Surg
20:744–752, 1996
14. BROWN EM, GAMBA G, RICCARDI D, LOMBARDI M, BUTTERS R,
KIFOR O, SUN A, HEDIGER MA, LYTTON J, HEBERT SC: Cloning and
characterization of an extracellular Ca(21)-sensing receptor from
bovine parathyroid. Nature 366:575–580, 1993
15. GARRETT JE, CAPUANO IV, HAMMERLAND LG, HUNG BC, BROWN
EM, HEBERT SC, FULLER F: Molecular cloning and functional expres-
sion of human parathyroid calcium receptor cDNAs. J Biol Chem
270:12919–12925, 1995
16. HEBERT SC, BROWN EM: The extracellular calcium receptor. Curr
Opin Cell Biol 7:484–492, 1995
17. BROWN EM, POLLAK M, RICCARDI D, HEBERT SC: Cloning and
characterization of an extracellular Ca(21)-sensing receptor from
parathyroid and kidney: New insights into the physiology and patho-
physiology of calcium metabolism. (editorial) Nephrol Dial Transplant
9:1703–1706, 1994
18. CHATTOPADHYAY N, MITHAL A, BROWN EM: The calcium-sensing
receptor: A window into the physiology and pathophysiology of
mineral ion metabolism. Endocr Rev 17:289–307, 1997
19. SILVER J, NAVEH-MANY T: Regulation of parathyroid hormone
synthesis and secretion. Semin Nephrol 14:175–194, 1994
20. POLLAK MR, BROWN EM, CHOU YH, HEBERT SC, MARX SJ, STEIN-
MANN B, LEVI T, SEIDMAN CE, SEIDMAN JG: Mutations in the human
Ca(21)-sensing receptor gene cause familial hypocalciuric hypercal-
cemia and neonatal severe hyperparathyroidism. (see comments) Cell
75:1297–1303, 1993
21. PEARCE SH, TRUMP D, WOODING C, BESSER GM, CHEW SL, GRANT
DB, HEATH DA, PATERSON CR, WHYTE MP, THAKKER RV: Calcium-
sensing receptor mutations in familial benign hypercalcemia and
neonatal hyperparathyroidism. J Clin Invest 96:2683–2692, 1995
22. HEATH H, ODELBERG S, JACKSON CE, TEH BT, HAYWARD N, LARSSON
C, BUIST NR, KRAPCHO KJ, HUNG BC, CAPUANO IV, GARRETT JE,
LEPPERT MF: Clustered inactivating mutations and benign polymor-
phisms of the calcium receptor gene in familial benign hypocalciuric
hypercalcemia suggest receptor functional domains. (see comments)
J Clin Endocrinol Metab 81:1312–1317, 1996
23. POLLAK MR, BROWN EM, ESTEP HL, MCLAINE PN, KIFOR O, PARK J,
HEBERT SC, SEIDMAN CE, SEIDMAN JG: Autosomal dominant hy-
pocalcemia caused by a Ca(21)-sensing receptor gene mutation.
Nature Genet 8:303–307, 1994
24. ORITA M, IWAHANA H, KANAZAWA H, HAYASHI K, SEKIYA T:
Detection of polymorphisms of human DNA by gel electrophoresis as
single-strand conformation polymorphisms. Proc Natl Acad Sci USA
86:2766–2770, 1989
25. ORITA M, SUZUKI Y, SEKIYA T, HAYASHI K: Rapid and sensitive
detection of point mutations and DNA polymorphisms using the
polymerase chain reaction. Genomics 5:874–879, 1989
26. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by
acid guanidinium thiocyanate-phenol-chloroform extraction. Anal
Biochem 162:156–159, 1987
27. AINSWORTH PJ, SURH LC, COULTER MACKIE MB: Diagnostic single
strand conformational polymorphism, (SSCP): A simplified non-
radioisotopic method as applied to a Tay-Sachs B1 variant. Nucl Acids
Res 19:405–406, 1991
Fig. 4. Representative single-strand
conformation polymorphism (SSCP) analysis of
the calcium receptor (CaR) gene without
differences in the band pattern: section of the
analysis of the PCR products containing exon 2
of various renal hyperparathyroid (rHPT)
patients. Lanes 1 and 2, patient 1; lanes 3 and
4, patient 2; lane 5, patient 3; lanes 6 and 7,
patient 4; lanes 8 and 9, patient 5; lanes 10 to
12, patient 6; lanes 13 and 14, patient 7; lanes
15 to 17, patient 8; lanes 18 to 20, patient 9;
lanes 21 to 23, patient 10.
Degenhardt et al: CaR point mutations and renal HPT560
28. MCCARRON DA, MUTHER RS, LENFESTY B, BENNETT WM: Parathy-
roid function in persistent hyperparathyroidism: Relationship to gland
size. Kidney Int 22:662–670, 1982
29. RUDBERG C, AKERSTROM G, LJUNGHALL S, GRIMELIUS L, JOHANSSON
H, PERTOFT H, WIDE L: Regulation of parathyroid hormone release in
primary and secondary hyperparathyroidism–Studies in vivo and in
vitro. Acta Endocrinol Copenh 101:408–413, 1982
30. CHOU YH, POLLAK MR, BRANDI ML, TOSS G, ARNQVIST H, ATKIN-
SON AB, PAPAPOULOS SE, MARX S, BROWN EM, SEIDMAN JG,
SEIDMAN CE: Mutations in the human Ca(21)-sensing-receptor gene
that cause familial hypocalciuric hypercalcemia. Am J Hum Genet
56:1075–1079, 1995
31. BAI M, QUINN S, TRIVEDI S, KIFOR O, PEARCE SHS, POLLAK MR,
KRAPCHO K, HEBERT SC, BROWN EM: Expression and characteriza-
tion of inactivating and activating mutations in the human Ca21-
sensing receptor. J Biol Chem 271:19537–19545, 1996
32. LOVLIE R, EIKEN HG, SORHEIM JI, BOMAN H: The Ca(21)-sensing
receptor gene (PCAR1) mutation T151 M in isolated autosomal
dominant hypoparathyroidism. Hum Genet 98:129–133, 1996
33. SHEFFIELD VC, BECK JS, KWITEK AE, SANDSTROM DW, STONE EM:
The sensitivity of single-strand conformation polymorphism analysis
for the detection of single base substitutions. Genomics 16:325–332,
1993
34. HOSOKAWA Y, POLLAK MR, BROWN EM, ARNOLD A: Mutational
analysis of the extracellular Ca(21)-sensing receptor gene in human
parathyroid tumors. J Clin Endocrinol Metab 80:3107–3110, 1995
35. KIFOR O, MOORE FD, WANG P, GOLDSTEIN M, VASSILEV P, KIFOR I,
HEBERT SC, BROWN EM: Reduced immunostaining for the extracel-
lular Ca21-sensing receptor in primary and uremic secondary hyper-
parathyroidism. J Clin Endocrinol Metab 81:1598–1606, 1996
36. GOGUSEV J, DUCHAMBON P, HORY B, GIOVANNINI M, GOUREAU Y,
SARFATI E, DRU¨EKE TB: Depressed expression of calcium receptor in
parathyroid gland tissue from patients with hyperparathyroidism.
Kidney Int 51:328–336, 1997
37. HSU CH, PATEL SR: Altered vitamin D metabolism and receptor
interaction with the target genes in renal failure: Calcitriol receptor
interaction with its target gene in renal failure. Curr Opin Nephrol
Hypertens 4:302–306, 1995
38. ROGERS KV, DUNN CK, CONKLIN RL, HADFIELD S, PETTY BA,
BROWN EM, HEBERT SC, NEMETH EF, FOX J: Calcium receptor
messenger ribonucleic acid levels in the parathyroid glands and kidney
of vitamin D-deficient rats are not regulated by plasma calcium or
1,25-dihydroxyvitamin D3. Endocrinology 136:499–504, 1995
39. BROWN AJ, ZHONG M, FINCH J, RITTER C, MCCRACKEN R, MORRIS-
SEY J, SLATOPOLSKY E: Rat calcium-sensing receptor is regulated by
vitamin D but not by calcium. Am J Physiol (Renal Fluid Electrol
Physiol) 270:F454–F460, 1996
Degenhardt et al: CaR point mutations and renal HPT 561
